Previously untreated patient 150-200 mg/m2 IV every 6 wk. May be given as a single dose or divided into daily inj of 75-100 mg/m2 on 2 successive days. Dose reduction w/ other myelosuppressive drugs or in whom bone marrow reserve is depleted. Doses subsequent to initial dose should be adjusted according to the hematologic response of the patient to the preceding dose.
Monitor complete blood counts wkly for at least 6 wk after a dose. Cases of fatal pulmonary toxicity. Close monitoring of the infusion site for possible infiltration during drug administration is recommended due to possibility of extravasation. Monitor long-term development of secondary malignancies. Ocular toxicity. Advise females of reproductive potential to use highly effective contraception during & after treatment for at least 6 mth after therapy & at least 3 mth after therapy for males of reproductive potential. Pregnancy. Discontinue use during lactation. Childn. Elderly.
Sign Out
